

19 *Corresponding author

20 E-mail: tsukinoki@kdu.ac.jp (KT)

21

22 **Abstract**

23 Abundant secretory IgA (sIgA) in mucus, breast milk, and saliva provides immunity that
24 prevents infection of mucosal surfaces. sIgA in pre-pandemic breast milk samples have
25 been reported to cross-react with SARS-CoV-2, but whether it also occurs in saliva and,
26 if so, whether it cross-reacts with SARS-CoV-2, has remained unknown. We aimed to
27 clarify whether sIgA in saliva cross-reacts with SARS-CoV-2 spike 1 subunit in
28 individuals who have not been infected with this virus. The study included 137 (male, n
29 = 101; female, n = 36; mean age, 38.7 [24–65] years) of dentists and doctors in the
30 Kanagawa Dental University Hospital. Saliva and blood samples were analyzed by PCR
31 and immunochromatography for IgG and IgM, respectively. We then identified patients
32 with saliva samples that were confirmed as PCR- and IgM-negative for COVID-19.
33 Proportions of SARS-CoV-2 cross-reactive IgA-positive individuals were determined by
34 enzyme-linked immunosorbent assay using a biotin-labeled spike S1-mFc recombinant
35 protein covering the receptor-binding domain of SARS-CoV-2. The proportion of SARS-
36 CoV-2 cross-reactive IgA-positive individuals was 46.7%, and this correlated negatively

37 with age ($r = -0.218$, $p = 0.01$). The proportion of IgA-positive individuals ≥ 50 y was
38 significantly lower than that of patients aged ≤ 49 y ($p = 0.008$). sIgA was purified from
39 the saliva of all patients, and the salivary sIgA was found to suppress the binding of
40 SARS-CoV-2 spike protein to the ACE-2 receptor. We found SARS-CoV-2 cross-reactive
41 sIgA in the saliva of some participants who had never been infected with the virus,
42 suggesting that sIgA helps prevent SARS-CoV-2 infection.

43

44 **Introduction**

45 Secretory IgA (sIgA) prevents infections through mucosal immunity, which is an aspect
46 of the immune system. sIgA, comprising dimeric IgA, a J chain, and a secretory
47 component, is secreted from glandular tissues such as salivary glands and mammary
48 glands onto mucosal surfaces, where it plays a central role in preventing the entry of
49 antigens from the mucosa [1]. Severe acute respiratory syndrome coronavirus 2 (SARS-
50 CoV-2) infects humans via the oral and nasal cavities, and the lungs [2]. The squamous
51 cells of the tongue and periodontal tissues express angiotensin-converting enzyme-2
52 (ACE-2), a SARS-CoV-2 receptor, transmembrane protease serin 2 (TMPRSS2), and furin,
53 which are proteases that promote infection [3], and saliva can harbor SARS-CoV-2 [4].
54 Saliva also contains several substances that suppress infection (such as lactoferrin,

55 lysozyme, and sIgA, which is the most abundant) and prevent the virus from entering
56 into the oral cavity [5].

57 Cross-reactive sIgA (CRsA) against SARS-CoV-2 was identified in breast milk before
58 the COVID-19 pandemic [6, 7]. Furthermore, SARS-CoV-2-reactive CD4+ T cells were
59 also detected in about 40%–60% of unexposed individuals before the pandemic,
60 suggesting that T cells have cross-reactivity to common cold coronaviruses and SARS-
61 CoV-2 [8]. Later findings [9, 10] suggested that prior infection with a coronavirus creates
62 immunological memory that is associated with sIgA cross-reactivity .

63 Infection with SARS-CoV-2 causes COVID-19, which manifests with a unique
64 spectrum of symptoms ranging from asymptomatic to fatal acute respiratory failure [11].
65 The severity and prevalence of SARS-CoV-2 infection noticeably differs among age
66 groups and countries, respectively [12]. Immune mechanisms might explain this wide
67 disparity, but they are not yet fully understood. Immunoglobulin G (IgG) can eliminate
68 SARS-CoV-2, and vaccine development against this virus is urgently needed [13].
69 However, mucosal immunity conferred by sIgA has not been investigated from the
70 viewpoints of recovery from SARS-CoV-2 infection and its prevention. New findings in
71 this area might facilitate deeper understanding of COVID-19 characteristics.

72 Therefore, we aimed to create an enzyme-linked immunosorbent assay (ELISA) for

73 detecting sIgA that has cross-reactivity with SARS-CoV-2, and revealed whether it has
74 salivary sIgA that cross-reacts with the SARS-CoV-2 spike 1 subunit for non-infected
75 individuals.

76

77 **Methods**

78 **Participant selection**

79 We tested saliva and blood samples using PCR and immunochromatography,
80 respectively. Individuals with saliva samples that were confirmed by PCR and IgM
81 testing as negative for COVID-19 were included. The participants included five doctors
82 and 132 dentists at the hospital attached to Kanagawa Dental University. Individuals
83 with IgA nephropathy, selective IgA deficiency, autoimmune diseases, or who had cold-
84 like symptoms within the past 2 weeks were excluded. We analyzed samples from 137
85 (male, n = 101; female, n = 36; mean age, 38.7 [24–65] years) individuals, under the fully
86 informed consent. This study was conducted under the approval of the Kanagawa Dental
87 University Research Ethics Review Board (Approval number: #690). This study was
88 registered in the Japanese clinical trial UMIN-CTR (Approval number: #R000046461)
89 registry, which meets ICMJE standards.

90

91 **Saliva collection for ELISA**

92 We collected samples using Salivettes® (Sarstedt AG & Co. KG, Nümbrecht, Germany)
93 at a fixed room of the hospital between 9 a.m. and 12 p.m. in August 2020, under the
94 infection control. The participants were instructed to refrain from eating, drinking, and
95 brushing their teeth for at least 1 hour before sample collection. The saliva samples were
96 immediately centrifuged at $2,000 \times g$ for 15 minutes and then stored at -80°C .

97

98 **Design of ELISA for cross-reactive sIgA (CRsA) against spike** 99 **protein**

100 We modified the ELISA system that could detect IgA cross-reactivity to influenza
101 viruses using human IgA ELISA quantitation set (#E88-102; Bethyl Laboratories,
102 Montgomery, TX, USA) reported by Yamamoto et al. [14]. Saliva samples was diluted
103 500-fold in carbonate-bicarbonate buffer and incubated for 1 hour at 25°C . Wells were
104 washed five times with wash solution. The antigen used recombinant spike 1-mFc
105 protein (#40591-V05H1; Sino Biological, Beijing, China) comprising the spike 1 subunit
106 with the spike protein receptor-binding domain (RBD) of SARS-CoV-2. The antigen was
107 labeled with biotin using a kit as described by the manufacturer (#BK01; Dojindo
108 Laboratories, Kumamoto, Japan). Biotin-labeled Spike 1 were added to a concentration

109 of 1 µg/mL into wells and incubated for 1 hour at 25°C. Wells were washed five times
110 with wash solution. Next, streptavidin-horseradish peroxidase conjugate (SA202;
111 Millipore, USA; dilution, 1:1000) was used and reacted for 1 hour at 25°C. TMB substrate
112 solution was added for 15 mins at 25°C and reaction was quenched with stop solution.
113 Spike 1 protein-bound IgA was determined at 450 nm using a microplate absorbance
114 reader (Bio-Rad Laboratories, Hercules, CA, USA). Background absorbance by the
115 negative control containing PBS was subtracted from the absorbance of all saliva
116 samples.

117

118 **IgA purification**

119 We purified sIgA using IgA purification kits (#20395; Thermo Fisher Scientific K.K.,
120 Waltham, MA, USA) as described by the manufacturer, then confirmed its molecular
121 weight by standard western blotting using primary anti-human IgA rabbit monoclonal
122 antibodies (ab184863; Abcam Plc, Cambridge, UK) diluted 1:500 and secondary anti-
123 rabbit polyclonal antibodies (#P0448; Dako A/S., Glostrup, Denmark; dilution, 1:1000).

124 ACE-2 binding to spike protein was inhibited by purified sIgA. We selected and
125 pooled the top 20 antibody-positive, and the bottom 20 antibody-negative samples based
126 on the ELISA results. The final concentrations of antibodies in the pooled positive and

127 negative saliva samples were 93.6 and 63.3 $\mu\text{g/mL}$, respectively.

128

129 **Ability of sIgA antibody to inhibit ACE-2-spike protein binding**

130 The ability of the sIgA to inhibit the binding of ACE-2 to SARS-CoV-2 spike protein
131 was assessed using SARS-CoV-2 spike-ACE-2 binding assay kits (#COV-SACE2-1;
132 RayBiotech, Peachtree Corners, GA, USA), according to the manufacturer. A SARS-CoV-
133 2 spike neutralizing rabbit IgG mAb (#40592-R001; Sino Biological) prepared as a
134 positive control and added neutralizing antibody at concentrations of 0, 0.0125, 0.025,
135 0.05, 0.1, and 0.2 $\mu\text{g/mL}$.

136

137 **Questionnaire**

138 Participants completed a self-administered questionnaire before saliva collection to
139 determine whether they had previously been inoculated with BCG, hepatitis B, and
140 influenza vaccines within the past year.

141

142 **Statistical analysis**

143 Negative values were set to 0 to determine relative ELISA values of CRsA, and
144 association with age was analyzed using Spearman rank correlations. Associations


145 between relative positive (> 0) and negative (0) values of CRsA in ELISA and binary
146 data, age group, gender, BCG vaccination status, hepatitis B vaccination status, and
147 influenza vaccine were examined. Associations with vaccination history were examined
148 using chi-square or Fisher exact tests. We summarized the variables of hepatitis B and
149 influenza vaccines as neither, either, or both to examine associations between the
150 number of vaccinations and IgA positivity or negativity. The variables of BCG, hepatitis
151 B vaccine, and influenza vaccine were summarized as zero, one, two, or three to examine
152 association between the number of vaccinations and IgA positivity or negativity. The
153 significance level was set to 5%. All data were statistically analyzed using SPSS version
154 26 (IBM Corp., Armonk, NY, USA).

155

156 **Results**

157 **Cross-reactive sIgA (CRsA) against spike protein**

158 The relative value of CRsA determined by ELISA was set to 0 as the negative value. The
159 CRsA was positive in 64 (46.7%) and negative in 73 (53.3%) samples.




160

161 **Fig. 1. Ratios (%) of detected cross-reactive antibodies to spike protein in saliva.**

162 Cross-reactive antibodies in saliva from 137 participants were detected by ELISA. Ratios

163 were calculated as positive or negative (absorbance 0 or less).

164



165

166 **Fig. 2. Associations between participant age and positive CRsA.**

167 Vertical axis: relative amount of IgA determined as absorbance of CRsA-positive
 168 participants. Negative samples are shown as 0. The absorbance was quite high among
 169 many participants aged ≤ 49 years.

170

171 Figure 2 showed associations between age and cross-reactive IgA. Age significantly
 172 and negatively correlated with relative CRsA ($r = -0.218$, $p = 0.01$). The positive rate of
 173 CRsA was significantly lower in participants aged ≥ 50 , compared with those aged ≤ 49
 174 years ($p = 0.008$). The association between vaccines and CRsA positivity or negativity
 175 was not significant.

176

177 **Table 1. Associations between age, sex, and vaccination and CRsA positivity.**

Variables		Total	IgA-positive		p*
		n	n	%	
Age (y)	20-29	32	19	59.4	0.081
	30-39	54	27	50.0	
	40-49	23	11	47.8	
	50-59	20	4	20.0	
	≥ 60	8	3	37.5	
	20-49	109	57	52.3	0.008
	≥ 50	28	7	25.0	
Sex	Male	101	48	47.5	0.452
	Female	36	16	44.4	
Vaccination					
BCG	Yes	102	49	48.0	0.781
	No	8	4	50.0	

	Unknown	27	11	40.7	
Hepatitis B	Yes	124	58	46.8	0.992
	No	11	5	45.5	
	Unknown	2	1	50.0	
Influenza	Yes	127	60	47.2	0.458
	No	10	4	40.0	
Hepatitis B and Influenza	Neither	1	1	100.0	0.114
	Either	19	7	36.8	
	Both	115	55	47.8	
BCG, Hepatitis B and Influenza	One	3	1	33.3	0.809
	Two	21	11	52.4	
	Three	84	40	47.6	

178 *Chi-square or Fisher exact tests.

179

180 CRsA inhibition tests

181 Western blots revealed purified IgA as a single band of ~ 60 kDa, confirming that the
182 protein was sIgA (data not shown).

183 In the positive control, the range of absorbance from the addition of spike neutralizing
184 antibody at different concentrations (0–0.2 µg/mL) was 2.155–0.493, with the
185 concentration-dependent decrease confirming neutralizing activity. The neutralizing
186 antibody against the spike protein showed an absorbance of 2.155 at an antibody
187 concentration of 0 µg/mL. This absorbance indicates the absorbance when ACE-2 and
188 the spike protein are most bound by ELISA. Since the CRsA-negative saliva sample
189 showed an absorbance of 2.402, which was 2.155 or higher, the binding between ACE-2

190 and the spike protein was not inhibited. The CRsA-positive saliva sample had an
191 absorbance of 1.678, and the binding between ACE-2 and spike protein was partially
192 inhibited.

193

194 **Discussion**

195 This study found that 46.7% of saliva samples from 137 participants contained CRsA
196 against SARS-CoV-2 spike 1. The spike 1 region that we examined included the RBD
197 that binds the SARS-CoV-2 receptor ACE-2. This region is important for preventing
198 infections and could thus be a target for vaccine development [14]. A previous ELISA of
199 SARS-CoV-2 CRsA in breast milk found positivity rates of 100% and 80%, respectively,
200 with the total spike protein and RBD as the antigen [6]. However, the salivary values in
201 the present study were lower than both of these. This might be because more sIgA is
202 produced in breast milk than in saliva [15]. The abundance of CRsA in breast milk is a
203 proven post-vaccination response [16], which could explain why the CRsA positivity rate
204 was lower in saliva than breast milk.

205 Participants with saliva samples that tested negative for COVID-19 determined by
206 PCR and antibody tests did not develop COVID-19 at the time of this article submission.
207 Thus, we believe that they had not been exposed to SARS-CoV-2. As such, we revealed

208 sIgA antibodies against the spike 1 protein of SARS-CoV-2 in individuals with no history
209 of SARS-CoV-2 infection. Only one other study found salivary IgA antibodies that cross-
210 react with the spike protein of SARS-CoV-2 before the COVID-19 pandemic [17]. The
211 nucleocapsid proteins of coronaviruses are highly homologous, but their spike proteins
212 share little commonality [18]. Patients with a history of infection with HCoV-OC43 and
213 other coronaviruses have antibodies against SARS-CoV-1 and antibodies that cross-react
214 to the SARS-CoV nucleocapsid protein, respectively [19]. Furthermore, whereas HCoV-
215 NL63 uses ACE-2 as a receptor, its spike protein shares little homology with SARS-CoV-
216 2 [20]. However, cross-reactivity of the receptor-binding motif 3 of NL63 and COV2-
217 SPIKE₄₂₁₋₄₃₄ of SARS-CoV-2 has recently been reported [20]. As past common
218 coronavirus infection can induce antibodies that are cross-reactive to spike and
219 nucleocapsid proteins, it is reasonable that saliva contains antibodies such as salivary
220 sIgA with cross-reactivity to SARS-CoV-2. However, the epitope behind salivary CRsA
221 cross-reactivity remains to be clarified.

222 The present study found that CRsA levels decreased with advancing age. This might
223 be explained by the fact that IgA levels decrease with age [21]. In addition, cross-reactive
224 IgG antibodies were identified in 62%, 43.75%, and 5.72% of serum samples from
225 individuals aged 1–16, 17–25, and ≥ 26 years, respectively, before the SARS-CoV-2

226 pandemic [9]. Because children are infected with common coronaviruses more frequently,
227 this seems to indicate that that more exposure leads to more individuals with cross-
228 reactive antibodies. Moreover, cross-reactive T cells for SARS-CoV-2 are rare in elderly
229 persons [22]. These results can explain why CRsA is prevalent in young persons but
230 uncommon in older persons. The mechanism behind the fact that COVID-19 is less
231 frequently severe and often asymptomatic in children [23] and adolescents [12] might be
232 partially explained.

233 We showed here that the binding between ACE-2 and spike protein was not inhibited
234 in individuals without CRsA. In contrast, because cross-reactive IgA inhibited the
235 binding of ACE-2 to spike protein, salivary CRsA might prevent SARS-CoV-2 infection
236 *via* a neutralization reaction, because IgA functions as a neutralizing antibody against
237 SARS-CoV-2 [24]. Although saliva contains SARS-CoV-2, it also contains infection
238 inhibitory factors [3]. Saliva lactoferrin is an infection suppressor that binds to SARS-
239 CoV-2 [25]. Because sIgA has an antigen-processing function that is synergistic with
240 lactoferrin, lysozyme, and peroxidase, salivary anti-bacterial or anti-viral factors might
241 enhance the action of CRsA [26].

242 Early SARS-CoV-2 specific humoral responses are dominated by IgA antibodies,
243 indicating that these play an important role in immunity after SARS-CoV-2 infection

244 [27]. On the other hand, neutralizing IgA antibodies against SARS-CoV-2 persist in
245 saliva for 49 to 73 days after symptoms appear [27]. Spike 1-CRsA in saliva is also
246 associated with the severity of pneumonia in COVID-19 [17]. Saliva can be collected
247 easily and noninvasively, and sIgA is a practical test specimen because it is resistant to
248 degradation and does not have strict transport conditions. Developing a method to easily
249 and non-invasively measure sIgA in saliva might be important for the diagnosis or risk
250 prediction of SARS-CoV-2 infection and responses to vaccines in the future.

251 One limitation of the present study was the low number of participants. Although
252 vaccines stimulate the production of cross-reactive antibodies [7], we found no significant
253 association between vaccines and cross-reactive antibodies. Future investigations should
254 compare individuals who are not involved in medical care (without experience of
255 vaccination).

256

257 **Conclusions**

258 This study identified the SARS-CoV-2 cross-reactive IgA spike protein in saliva from
259 individuals who have not experienced COVID-19. Elderly persons showed lower levels of
260 SARS-CoV-2 spike protein-CRsA than adolescents. Salivary IgA might block the binding
261 of ACE-2 to the spike protein. We revealed the importance of IgA as an inhibitor of SARS-

262 CoV-2 infection in the oral cavity. Our findings are novel, as few studies have examined
263 anti-SARS-CoV-2 antibodies in this compartment, despite the fact of the oral cavity being
264 a viral replication site [28].

265

266 **Acknowledgments**

267 We are grateful to Ms. Makiko Yamada at the Central Research Support Center of
268 Kanagawa Dental University Graduate School for providing valuable technical
269 assistance.

270

271 **Author contributions**

272 **Conceptualization:** Keiichi Tsukinoki.

273 **Data analysis:** Tatsuo Yamamoto.

274 **Sample collection:** Keisuke Handa, Mariko Iwamiya.

275 **Investigation:** Juri Saruta.

276 **Project administration:** Satoshi Ino.

277 **Supervision:** Takashi Sakurai.

278 **Funding acquisition:** Isamu Kashima.

279 **Writing-original draft:** Keiichi Tsukinoki.

280 **Writing-review:** Tatsuo Yamamoto, Keisuke Handa, Juri Saruta.

281

282 **References**

- 283 1. Yamamoto Y, To M, Hayashi T, Shimizu T, Kamata Y, Saruta J, et al. Intake of
284 indigestible carbohydrates influences IgA response and polymeric Ig receptor
285 expression in the rat submandibular gland. *Brit J Nutri.* 2015;113: 1859-1902.
- 286 2. Shi Y, Wang G, Cai X, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. *J*
287 *Zhejiang Univ Sci B.* 2020;21: 343-360. doi: 10.1631/jzus.B2000083.
- 288 3. Sakaguchi W, Kubota N, Shimizu T, Saruta J, Fuchida S, Kawata A, et al. Existence
289 of SARS - CoV - 2 entry molecules in the oral cavity. *Int J Mol Sci.* 2020;21(17):
290 6000. doi: 10.3390/ijms21176000.
- 291 4. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value
292 and transmission of 2019-nCoV. *Int J Oral Sci.* 2020;12: 11. doi: 10.1038/s41368-020-
293 0080-z.
- 294 5. Hayashi T, To M, Saruta J, Sato C, Yamamoto Y, Kondo Y, et al. Salivary lactoferrin
295 is transferred into the brain via the sublingual route. *Biosci Biotechnol*
296 *Biochem.* 2017;81: 1300-1304. doi: 10.1080/09168451.2017.1308241.
- 297 6. Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al.

- 298 Robust and specific secretory IgA against SARS-CoV-2 detected in human milk.
299 iScience. 2020;23(11): 101735. doi: 10.1016/j.isci.2020.101735.
- 300 7. Veronique DM, Dung MD , Gabrielle BM , David AS , Antti S , Kirsi MJ, et al.
301 Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-
302 reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. J Perinatol. 2020;1:
303 1-10. doi: 10.1038/s41372-020-00805-w.
- 304 8. Grifoni A, Weiskopf D, Ramirez SI, Mateus J Dan JM, Moderbacher CR, et al. Target
305 of T cell responses SARS-CoV-2 coronavirus in humans with COVID-19 disease and
306 unexposed individuals. Cell. 2020;181: 1489-1501.
- 307 9. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting
308 and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370: 1339-
309 1343.
- 310 10. Zhang J, Wu Q, Liu Z, Wang Q, Wu J, Hu Y, et al. Spike-specific circulating T
311 follicular helper cell and cross-neutralizing antibody responses in COVID-19-
312 convalescent individuals. Nat Microbiol. 2021;6(1): 51-58. doi: 10.1038/s41564-020-
313 00824-5.
- 314 11. Tyrpsteen W, Cleemput JV, van Snippenberg W, Gerio S, Vandekehoeve L. On the
315 whereabouts of SARS-CoV-2 in the human body: A systematic review.

- 316 PLoS Pathog. 2020;16(10): e1009037.
- 317 12. Watanabe S, Naito Y, Yamamoto T. Host factors that aggravate COVID-19
318 pneumonia. *Int J Family Med Primary Care*. 2020;1(3): 1-4.
- 319 13. Yamamoto Y, Saruta J, Takahashi T, To M, Shimizu T, Hayashi T, et al. Effect of
320 ingesting yogurt fermented with *Lactobacillus delbrueckii* ssp. *bulgaricus*
321 OLL1073R-1 on influenza virus-bound salivary IgA in elderly residents of nursing
322 homes: a randomized control trial. *Acta Odont Scand*. 2019;77(7): 517-524.
- 323 14. Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, et al. A cross-reactive human
324 IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. *Nat Commun*.
325 2020;11: 4198. doi: 10.1038/s41467-020-18058-8.
- 326 15. Brandtzaeg P. The secretory immune system of lactating human mammary glands
327 compared with other exocrine organs. *Ann N Y Acad Sci*. 1983;30(409): 353-382.
- 328 16. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody
329 responses as indirect measures of intestinal immunity after oral cholera vaccination
330 of natural disease. *J Clin Microbiol*. 1986;24(2): 203-209.
- 331 17. Varadhachary A, Chatterjee D, Garza J, Garr RP, Foley C, Letkeman A, et al.
332 Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity
333 against COVID-19. medRxiv. 2020;2020.08.07.20170258. doi:

- 334 10.1101/2020.08.07.20170258.
- 335 18. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, et al. Crystal structure of
336 SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique
337 drug targeting sites. *BioRxiv*. doi: <https://doi.org/10.1101/2020.03.06.977876>.
- 338 19. Patrick D, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden M, et al. An
339 outbreak of human coronavirus OC43 infection and serological cross-reactivity with
340 SARS coronavirus. *Can J Infect Dis Med Microbiol*. 2006;17(6): 330-336. doi:
341 0.1155/2006/152612.
- 342 20. Simula ER, Manca MA, Jasemi S, Uzzau S, Rubino S, Manchia P, et al. HCoV-NL63
343 and SARS-CoV-2 share recognized epitopes by the humoral response in sera of
344 people collected pre- and during CoV-2 pandemic. *Microorganisms*. 2020;8(12):
345 1993. doi: 10.3390/microorganisms8121993.
- 346 21. Tanida T, Ueta E, Tobiume A, Hamada T, Rao F, Osaki T. Influence of aging on
347 candida growth and adhesion regulatory agents in saliva. *J Oral Pathol Med*.
348 2001;30: 328-335.
- 349 22. Saletti G, Gerlach T, Jansen JM, Molle A, Elbahesh H, Ludlow M, et al. Older
350 adults lack SARS CoV-2 cross-reactive T lymphocyte directed to human OC43 and
351 NL63. *Scientific Rep*. 2020;10: 21447.

- 352 23. Tosif S, Neeland MR, Sutton P, Licciardi P, Sarkar S, Selva KJ, et al. Immune
353 responses to SARS-CoV-2 in three children of parents with symptomatic COVID-
354 19. *Nat Commun.* 2020;11: 5703.
- 355 24. Wang C, Li W, Dubravka D, Okabe NMA, van Haperen R, Osterhaus ADME, et al.
356 A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun.*
357 2020;11: 2251.
- 358 25. Hu Y, Meng X, Zhang F, Xiang Y, Wang J. The in vitro antiviral activity of
359 lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by
360 targeting the heparan sulfate co-receptor. *Emerg Microbes Infect.* 2021;10(1): 317-
361 330.
- 362 26. Rudney JD, Smith QT. Relationship between levels of lysozyme, lactoferrin,
363 salivary peroxidase and secretory immunoglobulin A in stimulated parotid saliva.
364 *Infect Immun.* 1985;49: 469-475.
- 365 27. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Clear L, et al. IgA dominates the
366 early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med.* 2020;13(577):
367 eabd2223. doi: 10.1126/scitranslmed.abd2223.

- 368 28. Isho B, Abe KT, Zuo M, Jamal A, Rathod B, Wang JH, et al. Persistence of serum
369 and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
370 Sci Immunol. 2020;5(52): eabe5511. doi: 10.1126/sciimmunol.abe5511.